Proposal for standardization of 2019-nCoV nucleic acid detection in clinical laboratories

Q4 Health Professions 中华检验医学杂志 Pub Date : 2020-03-11 DOI:10.3760/CMA.J.ISSN.1009-9158.2020.03.002

Y. Tong, Ming Wang, Wan-zhou Xu, B. Qiao, Hongyun Zheng, Si-qing Mei, Xiaoyun He, Pingan Zhang, Yan Li

{"title":"Proposal for standardization of 2019-nCoV nucleic acid detection in clinical laboratories","authors":"Y. Tong, Ming Wang, Wan-zhou Xu, B. Qiao, Hongyun Zheng, Si-qing Mei, Xiaoyun He, Pingan Zhang, Yan Li","doi":"10.3760/CMA.J.ISSN.1009-9158.2020.03.002","DOIUrl":null,"url":null,"abstract":"In December, the outbreak of a novel coronavirus (2019-nCoV) in Wuhan, China, has attracted extensive global attention. On January 20, 2020, the Chinese health authorities upgraded the coronavirus to a Class B infectious disease in the Law of the People′s Republic of China on the Prevention and Treatment of Infectious Diseases, and considered it as Class A infectious diseases in disease control and prevention. On January 18, 2020, the 2019-nCoV nucleic acid detection test was listed as the diagnostic criteria in the \"guidelines for diagnosis and treatment of pneumonia due to 2019-nCoV (Trial Version 2)\" . Therefore, standardizing the operation process of the 2019-nCoV nucleic acid detection in clinical laboratories has become a top priority. It is of paramount importance to establish standard protocols for detection of the 2019-nCoV nucleic acids in clinical laboratories to improve the reliability of the results and ensure the biosafety of laboratory personnel. \n \n \nKey words: \nCoronavirus; RNA, viral; Polymerase chain reaction; Laboratories, hospital; Medical laboratory science; Benchmarking; Containment of biohazards","PeriodicalId":10096,"journal":{"name":"中华检验医学杂志","volume":"92 1","pages":"209-212"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华检验医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1009-9158.2020.03.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 2

Abstract

In December, the outbreak of a novel coronavirus (2019-nCoV) in Wuhan, China, has attracted extensive global attention. On January 20, 2020, the Chinese health authorities upgraded the coronavirus to a Class B infectious disease in the Law of the People′s Republic of China on the Prevention and Treatment of Infectious Diseases, and considered it as Class A infectious diseases in disease control and prevention. On January 18, 2020, the 2019-nCoV nucleic acid detection test was listed as the diagnostic criteria in the "guidelines for diagnosis and treatment of pneumonia due to 2019-nCoV (Trial Version 2)" . Therefore, standardizing the operation process of the 2019-nCoV nucleic acid detection in clinical laboratories has become a top priority. It is of paramount importance to establish standard protocols for detection of the 2019-nCoV nucleic acids in clinical laboratories to improve the reliability of the results and ensure the biosafety of laboratory personnel. Key words: Coronavirus; RNA, viral; Polymerase chain reaction; Laboratories, hospital; Medical laboratory science; Benchmarking; Containment of biohazards

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

关于临床实验室新型冠状病毒核酸检测标准化的建议

去年12月，新型冠状病毒(2019-nCoV)在中国武汉爆发，引起全球广泛关注。2020年1月20日，中国卫生部门将新冠肺炎在《中华人民共和国传染病防治法》中升格为乙类传染病，在疾病预防控制中列为甲类传染病。2020年1月18日，《新型冠状病毒感染的肺炎诊疗指南(试行第二版)》将新型冠状病毒核酸检测试验列为诊断标准。．因此，规范临床实验室新型冠状病毒核酸检测的操作流程已成为当务之急。建立临床实验室新型冠状病毒核酸检测标准方案，提高检测结果的可靠性，确保实验室人员的生物安全至关重要。关键词:冠状病毒;RNA病毒;聚合酶链反应;实验室、医院;医学检验科学;基准测试;控制生物危害

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊